Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells
出版年份 2016 全文链接
标题
Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells
作者
关键词
-
出版物
Scientific Reports
Volume 6, Issue 1, Pages -
出版商
Springer Nature
发表日期
2016-05-25
DOI
10.1038/srep26803
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting TRAIL in the treatment of cancer: new developments
- (2015) Bora Lim et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
- (2015) Jean Jacques Grob et al. LANCET ONCOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing
- (2015) Y-T Oh et al. ONCOGENE
- Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling
- (2015) You-Take Oh et al. Oncotarget
- Mechanism and consequences of RAF kinase activation by small-molecule inhibitors
- (2014) M Holderfield et al. BRITISH JOURNAL OF CANCER
- Getting TRAIL back on track for cancer therapy
- (2014) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients WithBRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
- (2014) Douglas B. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- MEK and the inhibitors: from bench to bedside
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- B-Raf and the inhibitors: from bench to bedside
- (2013) Tiangui Huang et al. Journal of Hematology & Oncology
- Tumor adaptation and resistance to RAF inhibitors
- (2013) Piro Lito et al. NATURE MEDICINE
- Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma
- (2013) Geoffrey T. Gibney et al. Nature Reviews Clinical Oncology
- Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
- (2013) Alastair J. King et al. PLoS One
- Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors
- (2013) Tara R. Rheault et al. ACS Medicinal Chemistry Letters
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Retinoic Acid Enhances TRAIL-Induced Apoptosis in Cancer Cells by Upregulating TRAIL Receptor 1 Expression
- (2011) L. Dhandapani et al. CANCER RESEARCH
- Oncogenic Ras and B-Raf Proteins Positively Regulate Death Receptor 5 Expression through Co-activation of ERK and JNK Signaling
- (2011) You-Take Oh et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting RAF: trials and tribulations
- (2011) Julian Downward NATURE MEDICINE
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Recent Advances in the Research and Development of B-Raf Inhibitors
- (2010) Hui-Fang Li et al. CURRENT MEDICINAL CHEMISTRY
- Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation
- (2010) S. Mocellin CURRENT MEDICINAL CHEMISTRY
- Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation
- (2010) Annie Yang et al. CURRENT OPINION IN CELL BIOLOGY
- ERK/Ribosomal S6 Kinase (RSK) Signaling Positively Regulates Death Receptor 5 Expression through Co-activation of CHOP and Elk1
- (2010) You-Take Oh et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- New insights into apoptosis signaling by Apo2L/TRAIL
- (2010) F Gonzalvez et al. ONCOGENE
- Treatment combinations targeting apoptosis to improve immunotherapy of melanoma
- (2009) Peter Hersey et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Following TRAIL’s path in the immune system
- (2009) Christina Falschlehner et al. IMMUNOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started